Psychomotor and cognitive effects of piribedil,
a dopamine agonist, in young healthy volunteers
Schuck S, Bentue-Ferrer D, Kleinermans D,
Reymann JM, Polard E, Gandon JM, Allain H.
Laboratoire de Pharmacologie Experimentale et Clinique,
Universite de Rennes I - Faculte de Medecine,
CS 34317, 35 043 Rennes cedex, France.
Fundam Clin Pharmacol. 2002 Feb;16(1):57-65
ABSTRACTPiribedil is a dopamine agonist acting on D2 and D3 central nervous system dopamine receptors. This drug has been administered to 12 young healthy male volunteers (age 22 +/- 2 years) according to a single center randomized, double-blind, two ways cross-over, placebo controlled trial, including a washout period of one week. Placebo and piribedil were administered by a single intravenous infusion over 2 h (3 mg). Psychomotor performance and cognitive functions were assessed through a standardized and computerized psychometric tests battery and a continuous electroencephalogram (EEG) mapping. Piribedil improved simple reaction time (P=0.02), immediate (P=0.045 and 0.004), and delayed free recall (P=0.05), dual coding test (P=0.02) and increased theta and fast beta waves on the EEG (P < 0.05 and 0.001, respectively). No deleterious effect was observed on the tests exploring attention and concentration via the other procedures. It is concluded that a single intravenous perfusion of piribedil 3 mg improves alertness and the information processing speed within the central nervous system, in healthy volunteers.Piracetam
New brain cells
The memory switch?
Growing new brain cells
Piribedil (Trivastal) and Parkinson's disease
Refsand further reading
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family